Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 38

1.

Tumor-targeted TNFα stabilizes tumor vessels and enhances active immunotherapy.

Johansson A, Hamzah J, Payne CJ, Ganss R.

Proc Natl Acad Sci U S A. 2012 May 15;109(20):7841-6. doi: 10.1073/pnas.1118296109.

2.

Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner.

Chauhan VP, Stylianopoulos T, Martin JD, Popović Z, Chen O, Kamoun WS, Bawendi MG, Fukumura D, Jain RK.

Nat Nanotechnol. 2012 Apr 8;7(6):383-8. doi: 10.1038/nnano.2012.45.

3.

Therapeutic cancer vaccines: current status and moving forward.

Schlom J.

J Natl Cancer Inst. 2012 Apr 18;104(8):599-613. doi: 10.1093/jnci/djs033. Review.

4.

Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion.

Sorensen AG, Emblem KE, Polaskova P, Jennings D, Kim H, Ancukiewicz M, Wang M, Wen PY, Ivy P, Batchelor TT, Jain RK.

Cancer Res. 2012 Jan 15;72(2):402-7. doi: 10.1158/0008-5472.CAN-11-2464. Erratum in: Cancer Res. 2012 Jan 15;72(2):doi:10.1158/0008-5472.CAN-12-0113. Cancer Res. 2012 Mar 1;72(5):1316.

5.

Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy.

DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Keil SD, Junaid SA, Rugo HS, Hwang ES, Jirström K, West BL, Coussens LM.

Cancer Discov. 2011 Jun;1(1):54-67. doi: 10.1158/2159-8274.CD-10-0028.

6.

CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer.

Righi E, Kashiwagi S, Yuan J, Santosuosso M, Leblanc P, Ingraham R, Forbes B, Edelblute B, Collette B, Xing D, Kowalski M, Mingari MC, Vianello F, Birrer M, Orsulic S, Dranoff G, Poznansky MC.

Cancer Res. 2011 Aug 15;71(16):5522-34. doi: 10.1158/0008-5472.CAN-10-3143.

7.

Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kγ, a single convergent point promoting tumor inflammation and progression.

Schmid MC, Avraamides CJ, Dippold HC, Franco I, Foubert P, Ellies LG, Acevedo LM, Manglicmot JR, Song X, Wrasidlo W, Blair SL, Ginsberg MH, Cheresh DA, Hirsch E, Field SJ, Varner JA.

Cancer Cell. 2011 Jun 14;19(6):715-27. doi: 10.1016/j.ccr.2011.04.016.

8.

Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy.

Farsaci B, Higgins JP, Hodge JW.

Int J Cancer. 2012 Apr 15;130(8):1948-59. doi: 10.1002/ijc.26219.

9.

Molecular mechanisms and clinical applications of angiogenesis.

Carmeliet P, Jain RK.

Nature. 2011 May 19;473(7347):298-307. doi: 10.1038/nature10144. Review.

10.

Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication.

Quezada SA, Peggs KS, Simpson TR, Allison JP.

Immunol Rev. 2011 May;241(1):104-18. doi: 10.1111/j.1600-065X.2011.01007.x. Review.

11.

Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity.

Jochems C, Schlom J.

Exp Biol Med (Maywood). 2011 May 1;236(5):567-79. doi: 10.1258/ebm.2011.011007. Review.

12.

RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer.

Robert NJ, Diéras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, Perez EA, Yardley DA, Chan SY, Zhou X, Phan SC, O'Shaughnessy J.

J Clin Oncol. 2011 Apr 1;29(10):1252-60. doi: 10.1200/JCO.2010.28.0982.

PMID:
21383283
13.

Polarization of tumor-associated macrophages: a novel strategy for vascular normalization and antitumor immunity.

Huang Y, Snuderl M, Jain RK.

Cancer Cell. 2011 Jan 18;19(1):1-2. doi: 10.1016/j.ccr.2011.01.005.

14.

HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF.

Rolny C, Mazzone M, Tugues S, Laoui D, Johansson I, Coulon C, Squadrito ML, Segura I, Li X, Knevels E, Costa S, Vinckier S, Dresselaer T, Åkerud P, De Mol M, Salomäki H, Phillipson M, Wyns S, Larsson E, Buysschaert I, Botling J, Himmelreich U, Van Ginderachter JA, De Palma M, Dewerchin M, Claesson-Welsh L, Carmeliet P.

Cancer Cell. 2011 Jan 18;19(1):31-44. doi: 10.1016/j.ccr.2010.11.009.

15.

Lessons from the adjuvant bevacizumab trial on colon cancer: what next?

Van Cutsem E, Lambrechts D, Prenen H, Jain RK, Carmeliet P.

J Clin Oncol. 2011 Jan 1;29(1):1-4. doi: 10.1200/JCO.2010.32.2701. No abstract available.

PMID:
21115866
16.

HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment.

Corzo CA, Condamine T, Lu L, Cotter MJ, Youn JI, Cheng P, Cho HI, Celis E, Quiceno DG, Padhya T, McCaffrey TV, McCaffrey JC, Gabrilovich DI.

J Exp Med. 2010 Oct 25;207(11):2439-53. doi: 10.1084/jem.20100587.

17.

Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm.

Biswas SK, Mantovani A.

Nat Immunol. 2010 Oct;11(10):889-96. doi: 10.1038/ni.1937. Review.

PMID:
20856220
18.

Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression.

Madan RA, Gulley JL, Fojo T, Dahut WL.

Oncologist. 2010;15(9):969-75. doi: 10.1634/theoncologist.2010-0129.

19.

Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer.

Shrimali RK, Yu Z, Theoret MR, Chinnasamy D, Restifo NP, Rosenberg SA.

Cancer Res. 2010 Aug 1;70(15):6171-80. doi: 10.1158/0008-5472.CAN-10-0153.

20.

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.

Miles DW, Chan A, Dirix LY, Cortés J, Pivot X, Tomczak P, Delozier T, Sohn JH, Provencher L, Puglisi F, Harbeck N, Steger GG, Schneeweiss A, Wardley AM, Chlistalla A, Romieu G.

J Clin Oncol. 2010 Jul 10;28(20):3239-47. doi: 10.1200/JCO.2008.21.6457.

PMID:
20498403
Items per page

Supplemental Content

Support Center